Showing 5481-5490 of 7590 results for "".
- Billionaire John Paul DeJoria Bets Big on Aubío for Cold Sores and Maybe Morehttps://practicaldermatology.com/news/billionaire-john-paul-digorio-bets-on-aubo-for-cold-sores-and-maybe-more/2458461/Billionaire John Paul DiJoria of Paul Mitchell Professional Hair Care Products and Patron Tequila fame is putting his money where his mouth is --- literally. DeJoria is now investing “heavily” in a new natural and sustainably produced over-the-counter (OTC) col
- Fractional HiFR Helps Fight Signs of Aging on Lower Face/Neckhttps://practicaldermatology.com/news/fractional-hifr-helps-fight-signs-of-aging-on-lower-faceneck/2458469/Fractional high intensity focused radiofrequency (HiFR) is safe and effective in the treatment of mild to moderate laxity of the lower face and neck, new research suggests. The study was selected as Editor’s Choice in the July 2016 issue of
- Deadline Approaching: Apply for Grant from La Roche-Posay's "Dermatologist from the Heart" Programhttps://practicaldermatology.com/news/deadline-approaching-apply-for-grant-from-la-roche-posays-dermatologist-from-the-heart-program/2458476/La Roche-Posay plans to continue its "Dermatologist from the Heart" program for the fifth year. As part of the program, La Roche-Posay provides grant money up to $10,000 to fund community-oriented projects that ma
- Take That, Acne: BPX-01 Topical Gel Delivers Minocycline Precisely to the Skinhttps://practicaldermatology.com/news/take-that-acne-bpx-01-topical-gel-delivers-minocycline-precisely-to-the-skin/2458490/BioPharmX Corporation’s novel topical minocycline, BPX-01, may be as effective as its oral counterpart minus the systemic side effects, new research suggests. "These results are promising, that topical minocycline gel delivered as BP
- Novan: First Patient Dosed in Phase 2 Anti-Fungal Programhttps://practicaldermatology.com/news/nolan-first-patient-dosed-in-phase-2-anti-fungal-program/2458492/The first patient has been dosed in Novan's clinical program to evaluate the efficacy and safety of topical nitric oxide product candidate SB208 in the treatment of infections caused by dermatophytes such as Trichophyton rubrum (“T. rubrum”). Novan is developing
- Galderma Unveils the New Cetaphil Brand Graphics & Packaginghttps://practicaldermatology.com/news/galderma-unveils-the-new-cetaphil-brand-graphics-packaging/2458590/Galderma Laboratories, L.P., redesigned the graphics and packaging of its Cetaphil product line to provide a more simplified shopping experience at shelf, improved portfolio differentiation, as well as clarity of product benefits. "The packaging
- Kourtney Kardashian is Manuka Doctor's New Brand Ambassadorhttps://practicaldermatology.com/news/kourtney-kardashian-is-manuka-doctors-new-brand-ambassador/2458614/Kybella has Khloe, and now Manuka Doctors got Kourtney. Kourtney Kardashian is the new face of Manuka Doctor, a skincare line comprising Manuka Honey and patented Purified Bee Venom.
- Let the Sun Shine In? Research Reveals Why Sunbathers May Live Longer than Sun Avoidershttps://practicaldermatology.com/news/let-the-sun-shine-in-research-reveals-why-sunbathers-may-live-longer-than-sun-avoiders/2458634/Sunbathers tend to live longer than their shade-seeking counterparts despite their increased risk for skin cancer, but why? New research suggests that a decrease in heart disease and noncancer/non-heart disease deaths may explain the paradox.
- Cipher Pharmaceuticals Appoints New President and General Manager of US Businesshttps://practicaldermatology.com/news/cipher-pharmaceuticals-appoints-new-president-and-general-manager-of-us-business/2458662/Cipher Pharmaceuticals Inc. named Ralph Bohrer as President and General Manager of its US subsidiary. Mr. Bohrer is a seasoned pharmaceutical executive with 30 years of experience in sales and marketing leadership for growing dermatology companies. Prior to
- Valeant Pharmaceuticals Announces Management And Business Updatehttps://practicaldermatology.com/news/valeant-pharmaceuticals-announces-management-and-business-update/2458677/J. Michael Pearson has returned as Valeant Pharmaceuticals International, Inc.’s chief executive officer following his recovery from severe pneumonia and other complications. Howard B. Schiller, Valeant's interim chief executive officer, will transition out of his current duties but wil